Brent Morse Email & Phone Number

Boston, Ma, Us

Walnut Creek, California, Us

Cambridge, Massachusetts, Us

Leading process and analytical development efforts for genome-edited hematopoietic stem and progenitor cell (HSPC) and CAR-T products to advance Vor's therapeutic strategy. Established and built Process & Analytical Development group consisting of 20+ high performing scientists, associates, and process engineers. Delivered IND data package for VOR33, a CRISPR genome-edited HSPC product engineered to lack CD33

Cambridge, Massachusetts, Us

Boston, Ma, Us

Built analytical development group and oversaw the execution of the analytical strategy for characterization and release of editing reagents and drug product. Key contributor to multiple regulatory filings for Heme (CTX001) and CAR-T (CTX110, CTX120, CTX130) drug products.

Boston, Ma, Us

Developed biosimilarity/comparability protocols to evaluate biosimilars to Remicade, Humira, Actemra, and Soliris. Ensured that protocols were consistent with regulatory guidelines, included input of regulatory agencies and key opinion leaders, and were vetted and approved by upper management.

North Chicago, Illinois, Us

Used gene expression profiling techniques (Affymetrix) to characterize disease models and response to therapeutic drug exposure.

Developed assays to evaluate the cellular pharmacology of novel deuterium containing small molecule therapeutics. Supported CTP-221 (lenalidomide analogue for hematologic diseases) and CTP-499 (methylxanthine for chronic kidney disease).

Supported the discovery and development of Adnectins, novel protein therapeutics based on the 10th fibronectin type III domainDeveloped and led the tech transfer of the potency assay for CT322, an anti-angiogenic VEGFR-2 antagonist in Ph2 clinical studiesServed as Project Lead for Wnt pathway inhibitors that delivered both broad-spectrum and specific Wnt inhibitors within 12 monthsDeveloped cell-based assays for screening, lead selection, and early characterization of protein antagonists(TNFa, VEGFR-2, IGF-IR, PDGFRb, EGFR, DR5, IL-12, IL-6, PD-1/PD-L1, and Wnt), including bispecific antagonists (VEGFR-2/IGF-IR, VEGFR-2/PDGFRb, and VEGFR-2/EGFR)

Supported the development of Conversion Technology, a proprietary platform for converting a biological sample (human blood) from a diploid to haploid state through the creation of cell hybrids:• Automated existing cell culture platform: validated methods, trained staff, oversaw day to day operation• Collaborated with external consultants to design a LIMS interface• Developed proprietary stable cell line with enhanced cell fusion capability

Developed assays to characterize heat shock protein based cancer vaccines

Ms, Medicinal Chemistry & Molecular Pharmacology

Bs, Chemistry